DOCSLIB.ORG

Nuclear Medicine for Medical Students and Junior Doctors

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nuclear Medicine for Medical Students and Junior Doctors NUCLEAR MEDICINE FOR MEDICAL STUDENTS AND JUNIOR DOCTORS Dr JOHN W FRANK M.Sc, FRCP, FRCR, FBIR PAST PRESIDENT, BRITISH NUCLEAR MEDICINE SOCIETY DEPARTMENT OF NUCLEAR MEDICINE, 1ST MEDICAL FACULTY, CHARLES UNIVERSITY, PRAGUE 2009 [1] ACKNOWLEDGEMENTS I would very much like to thank Prof Martin Šámal, Head of Department, for proposing this project, and the following colleagues for generously providing images and illustrations. Dr Sally Barrington, Dept of Nuclear Medicine, St Thomas’s Hospital, London Professor Otakar Bělohlávek, PET Centre, Na Homolce Hospital, Prague Dr Gary Cook, Dept of Nuclear Medicine, Royal Marsden Hospital, London Professor Greg Daniel, formerly at Dept of Veterinary Medicine, University of Tennessee, currently at Virginia Polytechnic Institute and State University (Virginia Tech), Past President, American College of Veterinary Radiology Dr Andrew Hilson, Dept of Nuclear Medicine, Royal Free Hospital, London, Past President, British Nuclear Medicine Society Dr Iva Kantorová, PET Centre, Na Homolce Hospital, Prague Dr Paul Kemp, Dept of Nuclear Medicine, Southampton University Hospital Dr Jozef Kubinyi, Institute of Nuclear Medicine, 1st Medical Faculty, Charles University Dr Tom Nunan, Dept of Nuclear Medicine, St Thomas’s Hospital, London Dr Kathelijne Peremans, Dept of Veterinary Medicine, University of Ghent Dr Teresa Szyszko, Dept of Nuclear Medicine, St Thomas’s Hospital, London Ms Wendy Wallis, Dept of Nuclear Medicine, Charing Cross Hospital, London Copyright notice The complete text and illustrations are copyright to the author, and this will be strictly enforced. Students, both undergraduate and postgraduate, may print one copy only for personal use. Any quotations from the text must be fully acknowledged. It is forbidden to incorporate any of the illustrations or diagrams into any other work, whether printed, electronic or for oral presentation. [2] CONTENTS Introduction p 5 History p11 Clinical studies p19 Bone, soft tissue and infection p19 Breast p32 Sentinel node p37 Lymphatics p38 Cardiac p40 Endocrine p47 Pituitary p47 Thyroid p48 Parathyroid p52 Pancreas p54 Adrenals p57 Ovaries/testes p64 Neuroendocrine p64 Gastro-intestinal p67 Gastric emptying p67 Oesophageal transit p68 Inflammatory disease p70 Bleeding p73 Meckel’s p74 Hepato-biliary p75 Head and neck p82 Vocal cord p83 ‘lumps’ p84 Epiphora p86 [3] Brain p87 Tumour p87 Infection p88 Movement disorders p89 Dementias p92 Cerebral blood flow p94 Epilepsy p95 Lung and Chest p98 Paediatric p113 Renal p122 Static p123 Dynamic p128 Reflux p136 Vascular p139 Radionuclide therapy p142 The Future p149 Statistics p152 Legal requirements p153 Patient information p154 Quiz p156 Suggested reading and websites p178 [4] INTRODUCTION Principles There are four basic methods of imaging the body, using x-rays, gamma rays, sound waves and magnetism. Each has its own place, and they are complementary, not exclusive. X-rays, whether as conventional images or as CT, provide anatomical information. X-rays (first discovered by Röntgen in 1895) are produced when electrons from the cathode in the x-ray tube hit the anode, usually made of tungsten mounted on steel, which is angled so that the x-rays leave the tube and can be collimated into a beam. The energy of the x-rays is a measure of their penetrating power – the higher the energy, the more penetrating. The beam is then collimated, and passes through the area of the body under investigation. The x-rays are absorbed by the tissues through which they pass, and the denser the tissue, the more are absorbed. Thus, at an x-ray energy of 85kV which is normal for diagnostic imaging, air absorbs none and bone absorbs all, with other tissues absorbing a variable amount. Thus a ‘shadowgraph’ emerges and it is this that is imaged on the x-ray film. In CT there is no film, rather an array of detectors, which pick up the attenuated beam and process it. X-RAY ADULT PELVIS – SEX OF PATIENT? [5] CT SCAN UPPER ABDOMEN In both the conventional image and the CT image, the differential attenuation allows visualisation of the tissues. In Nuclear Medicine studies, a carrier molecule is labelled with a radio-active tracer, usually 99mTc, and this is injected into the patient. Thus in this case it is the patient who is the source of the radiation, which are gamma rays, and they are emitted all around the patient. Another major difference is that x-rays are only produced from the tube when the machine is activated and the current flows through the x-ray tube, and the duration of current flow is set by the radiographer. When there is no current, there are no x-rays emitted. However, the gamma rays are emitted continuously, but decaying all the time. Isotopes have a half life (t1/2) which varies from isotope to isotope. This is the time required for the activity to 99m fall to 50%. Tc has a t1/2 of 6 hours. Nuclear Medicine studies, using gamma rays, provide physiological information. Conventional radiography, CT, US and MRI all provide anatomical information. The isotope and carrier used depend on the organ or system to be studied, and will be detailed later. This means that the Nuclear Medicine image will not necessarily be anatomically recognisable, although in the case of bone scans it often is. [6] NORMAL ADULT BONE SCAN – FAIRLY ANATOMICAL TOXIC THYROID NODULE – NOT ANATOMICAL AT ALL [7] A patient who has been injected with a radio-active tracer is slightly radio-active, but the activity is constantly falling, both due to the physical t1/2 of the isotope, but also due to breakdown and excretion of the carrier molecules (the biological t1/2). The effective t1/2 can be defined thus: 1/ t1/2 eff = 1/ t1/2phys + 1/ t1/2biol Nuclear Medicine can be used to image most parts of the body, but some organs are imaged much more than others. Risks For short t1/2 isotopes administered in normal diagnostic doses, there is no risk to either the patient or anyone else. It is important to inform the patients of this because they may otherwise worry needlessly, especially as a lot of people equate radiation with atom bombs, Chernobyl, and so on. With most straightforward diagnostic scans, as opposed to therapeutic administration of isotopes, radiation levels are well within the normal variation of background radiation, e.g. watching TV. Patients who have had a diagnostic scan can go near pregnant women or children without causing them any harm, and the same applies after treatment for benign diseases with isotopes such as 131I for thyrotoxicosis. Obviously, the patient cannot ask every woman they stand next to if she is pregnant! Whilst theoretically non-ionising radiation is safe for use during pregnancy, in practice only Ultrasound is used. In all other imaging situations, it is crucial to ask female patients between the ages of 12 – 55 about sexual activity, contraception and the likelihood of pregnancy. In minors, such questioning must be done tactfully, with a female chaperone on hand, and without the patient’s parents. Some isotopes are excreted via the kidneys and bladder, so in patients suffering from urinary incontinence, care must be taken not to contaminate their bedding, chairs and so on, even with short t1/2 isotopes. This is more important when 131 patients are treated with longer t1/2 isotopes such as I. X-rays and gamma rays are both examples of ionising radiation, in comparison with Ultrasound and MRI which are non-ionising and so do not (theoretically) cause any cellular damage, and are thus safer. The most widely used non-ionising radiation imaging is Ultrasound, in which sound waves are emitted from a transducer and reflected back in varying amounts from every anatomical interface, detected, and an image produced. Ultrasound waves are totally reflected by bone or calcium-containing structures such as gall stones, which appear white and cast an acoustic shadow behind them, and pass totally through liquid such as urine in the bladder, causing acoustic enhancement behind the structure. [8] The investigation takes place in real time, making the interpretation much easier for the operator. UPPER ABDOMINAL ULTRASOUND SHOWING LIVER AND KIDNEY MRI does not use ionising radiation, but rather a strong magnetic field to align all the hydrogen protons. The alignment is then disrupted by properly tuned RF pulses. As the protons recover their alignment, they emit radio signals and these can be measured and converted by Fourier transforms in a computer to produce an image. The machine is large with a long central tunnel, in which the patient is placed. The walls are very near the patient to ensure an even magnetic field. MRI BRAIN SHOWING ALTERED SIGNAL IN RIGHT PARIETAL AREA – STROKE [9] LATERAL MRI OF LUMBAR SPINE Both US and MRI show anatomical information, but recent advances in MR imaging (fMRI) allow physiological information to be obtained, particularly in the brain. Due to the intense magnetic field, care must be taken that no magnetic objects are in the room, and the patients have to complete a questionnaire prior to imaging. Such a check list is reproduced here. MRI PATIENT CHECKLIST Some items can interfere with the examination, some can be hazardous to your health. Please check the following list carefully. Answer all questions. Please do not hesitate to ask staff for help if you have any queries. NAME: ......................... ,............................................. DATE OF BIRTH: ....................................... WEIGHT: ..................................................... 1. Do you have a pacemaker, artificial heart valve or coronary stent? 2. Do you have aneurysm clips in your head (from a surgical procedure)? 3. Do you have any metal implants e.g. joint replacements, pins, wires? 4. Do you have a cochlear implant? 5. Do you have an artificial limb, calliper or surgical corset? 6. Do you have any shrapnel or metal fragments in your body? 7.
Load more

Recommended publications
  • DICOM Conformance Template
    g GE Heathcare Technical Publications Direction 5507068-1EN (DOC1584283) Revision 1 DaTQUANT Application™ DICOM CONFORMANCE STATEMENT Copyright 2015 by General Electric Co. Do not duplicate g GE Heathcare LIST OF REVISIONS REV DATE DESCRIPTION PAGES APPR. 1 May 2015 Initial Release All M. Mesh DATQUANT APPLICATION GE Healthcare DICOM CONFORMANCE STATEMENT DIR 5507068-1EN (DOC1584283) REV 1 THIS PAGE LEFT INTENTIONALLY BLANK DATQUANT APPLICATION GE Healthcare DICOM CONFORMANCE STATEMENT DIR 5507068-1EN (DOC1584283) REV 1 CONFORMANCE STATEMENT OVERVIEW DaTQUANT application is an application that uses NM and CT images and creates NM, SC and MFSC images. Table 0.1 provides an overview of the network services supported by the DaTQUANT application. Table 0.1 – APPLICATION SOP Classes User of Object Creator of Instances Object Instances Transfer Secondary Capture Image Storage No Yes Multi-frame True Color Secondary Capture Image Storage No Yes Nuclear Medicine Image Storage Yes Yes Computerized Tomography Image Storage Yes No 4 DATQUANT APPLICATION GE Healthcare DICOM CONFORMANCE STATEMENT DIR 5507068-1EN (DOC1584283) REV 1 1. INTRODUCTION ............................................................................................................... 8 1.1 Overview ..................................................................................................................................................................... 8 1.2 Overall DICOM Conformance Statement Document Structure ..........................................................................
    [Show full text]
  • PET/CT Our First Experiences
    Renata Milardović, M.D. Nuclear Medicine University-Clinical Center Sarajevo Bosnia and Herzegovina • Research: > 30 years (cardiac, brain, bone) • 1980: First PubMed article published on clinical PET in German journal Herz (Geltman EM, Roberts R, Sobel BE. Cardiac positron tomography: current status and future directions. Herz 1980; 5:107-19) • Clinical breakthrough: last decade • Major propellers: Introduction of F18-fluoro-deoxyglucose Appearance of PET/CT (2001) • 2008-> all PET became PET/CT • Combines functional + structural information • Higher diagnostic accuracy • CT-based attenuation correction (faster) • Enables creation of an integrated report • Dominates the market today State-of-the-art New scintillators (faster) CT-based attenuation More detector rows correction (more axial slices) Smaller crystals (higher Increased x-ray tube spatial resolution) Multidetector arrays (fast, power (stability) high resolution) Increased computer Extended FOV (sensitivity) capacity (fast Time-of-flight (fewer artifacts) processing) Gating (motion correction) Faster rotation times New tracers (fewer motion artifacts) PET CT • First PET/CT scanner in BiH • Installed: mid2013 • Operational: 2014 • Discovery 600, General Electric Medical Systems • Dedicated PET scanner using BGO crystals • 16-slice multidetector CT scanner • 30 mm BGO crystals • Front/rear system panels • Improved patient controls • Increased vertical scan range Tema, Sinergie, OS: Windows Application: automatic. Sporadic Automated dispensing: reduced staff cases manual. One case exposure and accurate dosing automatic+manual. GE Healthcare OS: Linux 1. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 Ronald Boellaard, Mike J. O’Doherty, Wolfgang A. Weber, Felix M. Mottaghy, Markus N. Lonsdale, Sigrid G. Stroobants, Wim J. G. Oyen, Joerg Kotzerke, Otto S.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Auger Electrons for Cancer Therapy – a Review Anthony Ku1†, Valerie J
    Ku et al. EJNMMI Radiopharmacy and Chemistry (2019) 4:27 EJNMMI Radiopharmacy https://doi.org/10.1186/s41181-019-0075-2 and Chemistry REVIEW Open Access Auger electrons for cancer therapy – a review Anthony Ku1†, Valerie J. Facca1†, Zhongli Cai1 and Raymond M. Reilly1,2,3,4* * Correspondence: raymond.reilly@ utoronto.ca Abstract †Anthony Ku and Valerie J. Facca contributed equally to this work. Background: Auger electrons (AEs) are very low energy electrons that are emitted 111 67 99m 195m 125 1Department of Pharmaceutical by radionuclides that decay by electron capture (e.g. In, Ga, Tc, Pt, I Sciences, University of Toronto, and 123I). This energy is deposited over nanometre-micrometre distances, resulting in Toronto, ON, Canada 2Department of Medical Imaging, high linear energy transfer (LET) that is potent for causing lethal damage in cancer University of Toronto, Toronto, ON, cells. Thus, AE-emitting radiotherapeutic agents have great potential for treatment of Canada cancer. In this review, we describe the radiobiological properties of AEs, their Full list of author information is available at the end of the article radiation dosimetry, radiolabelling methods, and preclinical and clinical studies that have been performed to investigate AEs for cancer treatment. Results: AEs are most lethal to cancer cells when emitted near the cell nucleus and especially when incorporated into DNA (e.g. 125I-IUdR). AEs cause DNA damage both directly and indirectly via water radiolysis. AEs can also kill targeted cancer cells by damaging the cell membrane, and kill non-targeted cells through a cross-dose or bystander effect. The radiation dosimetry of AEs considers both organ doses and cellular doses.
    [Show full text]
  • Lettirs to Th Editor Radiation Injury from Interstitial Injection Of
    DEPARTMENTS Lettirs to th Editor Radiation Injury from Interstitial Injection of measuring approximately 2 cm x 1 cm. Monitoring of the site Iodine-131-Iodocholesterol demonstrated retention of 131!(Fig. 2). On the basis of serial counts, the half-time was 5.5 days at the i.v. injection site. TO THE EDITOR: A 44-yr-oldman wasinvestigatedfor recur The absorbeddose deliveredto the overlyingskin cannot be rent Cushing's disease. An adrenal gland scan was initiated with precisely calculated because it has a very strong inverse depend injection of 34-MBq of ‘31I-iodocholesterol over a 5-mm interval. ence on the interstitial volume occupied by the injectate, and this Prior to injection, blood was withdrawn into the hub of the volume is not accurately known. The absorbed dose can be syringe to ensure correct i.v. placement. At the conclusion of the estimated by treating the interstitial volume occupied by the injection, the patient volunteered that the injection had been the injectate as a disk of the same area as the erythematous patch; least painful i.v. entry he had experienced. Seven days later, the thickness of this volume can be roughly estimated. The imaging failed to detect any radioactivity in the field of view volumeofdistributionwasassumedto remainconstantovertime centered on the adrenal glands. Monitoring of the injection site since the injectate is not water-soluble. The absorbed dose in this demonstrated essentially complete retention of the radiophar volume can be calculated by the method of Johns and Cun maceutical at the site. ningham (1). Because the model assumes no activity outside the The patient returned 13 days later (i.e., 20 days after the volume,the absorbeddose in the regionadjacentto this volume injection) to inquire about the tender pruritic and erythematous within the range of the beta particles (i.e., the skin) can be patch at the injection site at which time the photograph in Figure estimated to be halfthe dose inside the volume.
    [Show full text]
  • Nuclear Pharmacy Quick Sample
    12614-01_CH01-rev3.qxd 10/25/11 10:56 AM Page 1 CHAPTER 1 Radioisotopes Distribution for Not 1 12614-01_CH01-rev3.qxd 10/25/1110:56AMPage2 2 N TABLE 1-1 Radiopharmaceuticals Used in Nuclear Medicine UCLEAR Chemical Form and Typical Dosage P Distribution a b HARMACY Radionuclide Dosage Form Use (Adult ) Route Carbon C 11 Carbon monoxide Cardiac: Blood volume measurement 60–100 mCi Inhalation Carbon C 11 Flumazenil injection Brain: Benzodiazepine receptor imaging 20–30 mCi IV Q UICK Carbon C 11 Methionine injection Neoplastic disease evaluation in brain 10–20 mCi IV R Carbon C 11 forRaclopride injection Brain: Dopamine D2 receptor imaging 10–15 mCi IV EFERENCE Carbon C 11 Sodium acetate injection Cardiac: Marker of oxidative metabolism 12–40 mCi IV Carbon C 14 Urea Diagnosis of Helicobacter pylori infection 1 µCi PO Chromium Cr 51 Sodium chromate injection Labeling red blood cells (RBCs) for mea- 10–80 µCi IV suring RBC volume, survival, and splenic sequestration Cobalt Co 57 Cyanocobalamin capsules Diagnosis of pernicious anemia and 0.5 µCi PO Not defects of intestinal absorption Fluorine F 18 Fludeoxyglucose injection Glucose utilization in brain, cardiac, and 10–15 mCi IV neoplastic disease Fluorine F 18 Fluorodopa injection Dopamine neuronal decarboxylase activity 4–6 mCi IV in brain Fluorine F 18 Sodium fluoride injection Bone imaging 10 mCi IV Gallium Ga 67 Gallium citrate injection Hodgkin’s disease, lymphoma 8–10 mCi IV Acute inflammatory lesions 5 mCi IV Indium In 111 Capromab pendetide Metastatic imaging in patients with biopsy-
    [Show full text]
  • Advantages of Hybrid SPECT/CT Vs SPECT Alone Heather A
    The Open Medical Imaging Journal, 2008, 2, 67-79 67 Open Access Advantages of Hybrid SPECT/CT vs SPECT Alone Heather A. Jacene*,1, Sibyll Goetze1,2, Heena Patel1, Richard L. Wahl1 and Harvey A. Ziessman1 1Division of Nuclear Medicine, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hop- kins University, Baltimore, MD, USA 2Current Address: Department of Radiology, University of Alabama, Birmingham, AL, USA Abstract: We present our initial two year clinical experience with SPECT/CT, compare the interpretation to SPECT alone, provide illustrative cases, and review the published literature. Hybrid SPECT/CT has added clinical value over SPECT imaging alone primarily due to more precise anatomical lesion localization. After reading this report, the reader will appreciate the advantages of SPECT/CT imaging for clinical practice. We have reviewed SPECT/CT studies of 144 adult patients referred for various clinical indications in a busy nuclear medicine practice. The SPECT and fused SPECT/CT images were reviewed and interpreted separately to determine if addition of the fused CT images added in- cremental information, e.g., more definitive anatomic localization, more definitive diagnostic certainty, or changed final image interpretation compared to the SPECT images alone. Our analysis showed that SPECT/CT provided additional in- formation for image interpretation in 54% (78/144) of cases. In most of these (68/78), the CT data improved localization of abnormal and physiologic findings. Diagnostic certainty was improved in 34/144 cases (24%) and image interpretation was beneficially altered in 18/144 cases (13%). The fusion of anatomical and functional information by hybrid SPECT/CT positively impacts image interpretation and adds diagnostic value over SPECT alone.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Diagnostic Performance of Contrast-Enhanced Ultrasound For
    www.nature.com/scientificreports OPEN Diagnostic performance of contrast‑enhanced ultrasound for acute pyelonephritis in children Hyun Joo Jung1, Moon Hyung Choi2, Ki Soo Pai1 & Hyun Gi Kim2,3* The objective of our study was to evaluate the performance of renal contrast‑enhanced ultrasound (CEUS) against the 99m-labeled dimercaptosuccinic acid (DMSA) scan and computed tomography (CT) in children for the diagnosis of acute pyelonephritis. We included children who underwent both renal CEUS and the DMSA scan or CT. A total of 33 children (21 males and 12 females, mean age 26 ± 36 months) were included. Using the DMSA scan as the reference standard, the sensitivity, specifcity, positive predictive value, and negative predictive value of CEUS was 86.8%, 71.4%, 80.5%, and 80.0%, respectively. When CT was used as the reference standard, the sensitivity, specifcity, positive predictive value, and negative predictive value of CEUS was 87.5%, 80.0%, 87.5%, and 80.0%, respectively. The diagnostic accuracy of CEUS for the diagnosis of acute pyelonephritis was 80.3% and 84.6% compared to the DMSA scan and CT, respectively. Inter-observer (kappa = 0.54) and intra-observer agreement (kappa = 0.59) for renal CEUS was moderate. In conclusion, CEUS had good diagnostic accuracy for diagnosing acute pyelonephritis with moderate inter‑ and intra‑observer agreement. As CEUS does not require radiation or sedation, it could play an important role in the future when diagnosing acute pyelonephritis in children. Urinary tract infection (UTI) is a common cause of illness with fever in children. It frequently develops in boys during their frst year of life and is more frequent in girls of older ages 1.
    [Show full text]
  • Radionuclides in Nephrourology, Part 2: Pitfalls and Diagnostic Applications
    Journal of Nuclear Medicine, published on March 3, 2014 as doi:10.2967/jnumed.113.133454 CONTINUING EDUCATION Radionuclides in Nephrourology, Part 2: Pitfalls and Diagnostic Applications Andrew T. Taylor Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the common clinical indications of suspected obstruction and renovascular hypertension; (2) the status of radionuclide renal imaging in the evaluation of the transplanted kidney and the detection of infection; and (3) potential pitfalls. Financial Disclosure: This review was partially supported by a grant from the National Institutes of Health (NIH/NIDDK R37 DK38842). Andrew T. Taylor is entitled to a share of the royalties for the use of QuantEM software for processing MAG3 renal scans, which was licensed by Emory University to GE Healthcare in 1993. He and his coworkers have subsequently developed in-house, noncommercial software that was used in this study and could affect their financial status. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict-of-interest policies. The author of this article has indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity.
    [Show full text]
  • Introducing PET/CT at AIMS, Kochi
    Nuclear medicine investigations use small amounts of FDA approved sterile radioactive materials for imaging. These investigations are safe, can be used in all age groups even extremes of age and are painless. Small amounts of radiopharmaceuticals are introduced into the body by injection, swallowing, or inhalation. These radiopharmaceuticals are substances, which are organ specific and get bound within a period of time to the organ and facilitate imaging. The amount of radiopharmaceutical used is carefully selected to provide the least amount of radiation exposure to the patient but ensure an accurate test. A special camera (PET, SPECT gamma camera) is then used to take pictures of your body. The camera detects the radiopharmaceutical in the organ, bone or tissue and forms images that provide data and information about the area in question. Nuclear medicine differs from an x-ray, ultrasound or other diagnostic test because it determines the presence of disease based on biological changes rather than changes in anatomy. Hence it helps in early detection of a disease much before other anatomical imaging modality picks up. GAMMA CAMERA (SPECT/CT) GAMMA CAMERA APPLICATIONS: Cardiac Applications: Coronary Artery Disease Measure Effectiveness of Bypass Surgery Measure Effectiveness of Therapy for Heart Failure Detect Heart Transplant Rejection Select Patients for Bypass or Angioplasty Identify Surgical Patients at High Risk for Heart Attacks Identify Right Heart Failure Measure Chemotherapy Cardiac Toxicity Evaluate Valvular Heart Disease Identify
    [Show full text]
  • Evidence-Based Indications for the Use of PET-CT in the UK 2016
    Evidence-based indications for the use of PET-CT in the United Kingdom 2016 _________________________________ The Royal College of Radiologists, Royal College of Physicians of London, Royal College of Physicians and Surgeons of Glasgow, Royal College of Physicians of Edinburgh, British Nuclear Medicine Society, Administration of Radioactive Substances Advisory Committee Contents Foreword 1 Non-FDG tracers for clinical practice 10 Indications for non-FDG tracers 10 Indications for 18F-fluorodeoxyglucose (FDG) PET-CT 3 Key references 13 Oncology applications 3 Indications for FDG scans 13 Non-oncological applications 8 Indications for non-FDG scans 25 1 www.rcr.ac.uk Foreword Since its introduction into clinical practice in the UK 26 years ago, positron emission tomography (PET) followed by positron emission tomography-computed tomography (PET-CT) has become a key investigative tool in the assessment of cancer and non-cancer medical conditions. The Inter-Collegiate Standing Committee on Nuclear Medicine (ICSCNM) supported the development of PET-CT in the UK through a number of initiatives including the 2003 document Positron emission tomography – A strategy for provision in the UK, the forerunner of the publication PET-CT in the UK. A strategy for development and integration of a leading edge technology within routine clinical practice in the UK. The publication of the first version of Evidence-based indications for the use of PET-CT in the United Kingdom 2012 was a landmark ICSCNM document. Authored by Sally Barrington and Andrew Scarsbrook, it provided, for the first time, a guide to the use of PET-CT in clinical practice and the evidence-base on which this was founded.
    [Show full text]